Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy

Background:Little is known about the prevalence and pattern of hepatitis B virus (HBV) mutations in HIV/HBV co-infected individuals on long-term lamivudine (3TC) therapy. Methods:HBV polymerase/envelope/basal core promoter/pre-core sequences from 81 HIV–HBV co-infected persons who received at least 6 months 3TC were compared to HBV reference sequences. Host and viral characteristics associated with HBV mutations were determined. Results:HBV viraemia was detected in 53 persons (65%) and was associated with lower CD4 cell count nadir and higher HIV RNA at the time of testing but not with 3TC duration. Known 3TC-resistant mutations occurred in 50% and 94% of viremic patients with < 2 years and > 4 years 3TC, respectively. The CD4 cell count at testing was significantly higher in those with 3TC-resistant mutations. The triple polymerase mutant (rtL173V, rtL180M, rtM204V), which behaves as a vaccine escape mutant in vitro, occurred in 17% of viraemic patients. Polymerase mutations that may confer resistance to other anti-HBV agents were also detected. Conclusions:In HIV–HBV co-infected patients, greater immunocompromise is associated with continued HBV viraemia while on 3TC, and development of 3TC-resistant mutations are inevitable with prolonged 3TC use. These mutant viruses may limit future therapeutic options due to cross-resistance or may produce HBV vaccine escape mutants. Thus, timing and selection of antiretroviral therapy is critical in this population.

[1]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[2]  Ching-lung Lai,et al.  Four years of lamivudine treatment in Chinese patients with chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[3]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[4]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[5]  A. McNaghten,et al.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.

[6]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[7]  S. Lewin,et al.  Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV–HBV co-infected individuals , 2003, AIDS.

[8]  C. Boucher,et al.  The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count) , 2003, AIDS.

[9]  K. Petoumenos,et al.  HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy , 2003, HIV medicine.

[10]  P. Marcellin,et al.  Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. , 2002, Gastroenterology.

[11]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[12]  D. Jackson,et al.  Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. , 2002, Virology.

[13]  Alan S. Perelson,et al.  Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed , 2001, Hepatology.

[14]  Y. S. Kim,et al.  Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. , 2001, Journal of Korean medical science.

[15]  F. Donato,et al.  Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.

[16]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[17]  D. Cooper,et al.  Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. , 1999, The Journal of infectious diseases.

[18]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[19]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[20]  A. Lok,et al.  Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion , 1999, Hepatology.

[21]  A. Bertoletti,et al.  Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. , 1998, The Journal of clinical investigation.

[22]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[23]  W. Carman,et al.  The clinical significance of surface antigen variants of hepatitis B virus , 1997, Journal of viral hepatitis.

[24]  M. Manns,et al.  Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. , 1997, Journal of hepatology.

[25]  A. Vaheri,et al.  Seroprevalence and coprevalence of HIV and HBsAg in Nigerian children with/without protein energy malnutrition. , 1997, Acta tropica.

[26]  R. Tedder,et al.  Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection , 1997, AIDS.

[27]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Poynard,et al.  Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients , 1995, The Lancet.

[29]  D. Cooper,et al.  The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. , 1991, The Journal of infectious diseases.

[30]  R. Brookmeyer,et al.  Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. , 1987, American journal of epidemiology.

[31]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[32]  S. Locarnini,et al.  HBV genotyping and analysis for unique mutations. , 2004, Methods in molecular medicine.

[33]  S. Locarnini.  Hepatitis B viral resistance: mechanisms and diagnosis. , 2003, Journal of hepatology.

[34]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. , 1998, Hepatology.

[35]  S. Mishiro,et al.  Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates , 1998, Archives of Virology.